| Medical and Health Sciences | Lifetime | 422 | NL 9 | 99.98 |
| Medical and Health Sciences | 2021-2025 | 828 | NL 18 | 99.81 |
| Psychiatry and Mental health | Lifetime | 23 | NL 2 | 99.94 |
| Medical Physiology | Lifetime | 54 | NL 2 | 99.92 |
| Neuroscience of Neurology | Lifetime | 88 | NL 1 | 99.27 |
| Radiology, Nuclear Medicine and Imaging | Lifetime | 246 | NL 6 | 99.38 |
| Cognitive Neuroscience | Lifetime | 367 | NL 14 | 99.20 |
| Clinical Neurology | Lifetime | 464 | NL 17 | 98.03 |
| Medical Physiology | 2021-2025 | 66 | NL 2 | 99.14 |
| Psychiatry and Mental health | 2021-2025 | 93 | NL 3 | 98.45 |
| Cognitive Neuroscience | 2021-2025 | 556 | NL 22 | 89.16 |
| Clinical Neurology | 2021-2025 | 547 | NL 16 | 77.32 |
| Health, Toxicology and Mutagenesis | 2021-2025 | 970 | NL 21 | 61.54 |
| Neurological Disease Mechanisms and Treatments | Lifetime | 1 | NL 1 | 99.97 |
| Dementia and Cognitive Impairment Research | Lifetime | 8 | NL 1 | 99.97 |
| Alzheimer's disease research and treatments | Lifetime | 19 | NL 1 | 99.95 |
| Functional Brain Connectivity Studies | Lifetime | 53 | NL 2 | 99.83 |
| Advanced Neuroimaging Techniques and Applications | Lifetime | 39 | NL 1 | 99.76 |
| Neuroprotection in Stroke and Neurodegeneration | Lifetime | 27 | NL 2 | 99.61 |
| Cerebrovascular and genetic disorders | Lifetime | 9 | NL 1 | 99.29 |
| Cholinesterase and Neurodegenerative Diseases | Lifetime | 73 | NL 1 | 99.19 |
| Cerebrovascular and Carotid Artery Diseases | Lifetime | 202 | NL 19 | 99.37 |
| EEG and Brain-Computer Interfaces | Lifetime | 272 | NL 12 | 98.99 |
| S100 Proteins and Annexins | Lifetime | 131 | NL 6 | 98.32 |
| Aging, Elder Care, and Social Issues | Lifetime | 243 | NL 8 | 95.16 |
| Health Systems, Economic Evaluations, Quality of Life | Lifetime | 524 | NL 41 | 98.70 |
| Neurological and metabolic disorders | Lifetime | 73 | NL 2 | 98.06 |
| Acute Ischemic Stroke Management | Lifetime | 586 | NL 31 | 98.38 |
| Advanced MRI Techniques and Applications | Lifetime | 798 | NL 40 | 98.21 |
| Intracerebral and Subarachnoid Hemorrhage Research | Lifetime | 308 | NL 18 | 97.70 |
| Health, Environment, Cognitive Aging | Lifetime | 239 | NL 6 | 96.35 |
| Cancer-related cognitive impairment studies | Lifetime | 407 | NL 33 | 91.99 |
| Ginkgo biloba and Cashew Applications | Lifetime | 278 | NL 2 | 90.20 |
| Biological Research and Disease Studies | Lifetime | 39 | NL 1 | 82.89 |
| Cognitive Functions and Memory | Lifetime | 960 | NL 33 | 72.51 |
| Alzheimer's disease research and treatments | 2021-2025 | 26 | NL 4 | 99.71 |
| Dementia and Cognitive Impairment Research | 2021-2025 | 153 | NL 8 | 98.45 |
| Cholinesterase and Neurodegenerative Diseases | 2021-2025 | 61 | NL 1 | 95.47 |
| Functional Brain Connectivity Studies | 2021-2025 | 423 | NL 17 | 96.20 |
| Health Systems, Economic Evaluations, Quality of Life | 2021-2025 | 546 | NL 34 | 95.33 |
| Cancer-related cognitive impairment studies | 2021-2025 | 109 | NL 10 | 91.50 |
| Health, Environment, Cognitive Aging | 2021-2025 | 720 | NL 29 | 80.65 |
| Amyotrophic Lateral Sclerosis Research | 2021-2025 | 682 | NL 21 | 80.76 |
| Neuroprotection in Stroke and Neurodegeneration | 2021-2025 | 424 | NL 6 | 76.64 |
| Neurological Disease Mechanisms and Treatments | 2021-2025 | 852 | NL 28 | 73.71 |
| S100 Proteins and Annexins | 2021-2025 | 667 | NL 20 | 66.23 |
| Cognitive Functions and Memory | 2021-2025 | 398 | NL 13 | 54.23 |
| Cerebrovascular and genetic disorders | 2021-2025 | 570 | NL 52 | 44.07 |
